Read/Post Comments (0) | Recommended this article (0)
Please login to Zacks.com or register to post a comment.
Zacks' 7 Best Stocks
for June, 2013
FREE Report for Zacks.com
Visitors Only
Visitors Only
They're hand-picked from the list of Zacks Rank #1 Strong Buys. Our experts predict that their prices will jump the soonest.
Today, you can see them free.
- Latest News
- Most Popular
- 3 Dreamy Small-Cap Stocks
- Correction or Summer Range Trade?
- Hitting Home Runs & Grand Slams, Not Loud Outs
- Hedge Your Portfolio with the Equity Bear ETF
- Machinery Industry Stock Outlook - May 2013
- Determining Correct Position Size with Options
- This Week's Growth & Income Stocks
- RTI: Do Stocks Tank When QE Ends?
- 3 Top-Ranked Consumer ETFs to Buy Now
- AWS 5/23: Is the Market Over-Reacting?
- PFP 5/23: Do No Harm
Recent Quotes
| No Recent Quote currently available |
My Portfolio
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
More Zacks Resources
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
Zacks #1 Stocks on the Move 05/23/2013
| Company Name | Symbol | %Change |
|---|---|---|
| WESTELL TECH | WSTL | 6.67% |
| STEIN MART I | SMRT | 5.38% |
| ALLIANCE FIB | AFOP | 5.21% |
| DAWSON GEOPH | DWSN | 4.33% |
| MARRIOTT VAC | VAC | 3.27% |
Quick Links
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
Leading radiosurgery systems maker Accuray Incorporated ( ARAY - Analyst Report ) recently revealed that it inked a collaboration and research agreement with Erasmus Medical Center (MC), the largest university medical center in the Netherlands. As per the agreement, the two parties will collaborate on research in the field of radiation oncology with the purpose of giving healthcare practitioners the latest tools for patient care.
The two sides already have an extended history of collaboration. Erasmus MC’s clinical expertise with Accuray’s CyberKnife System enables it to appreciate the benefits derived by cancer patients from radiosurgery. It looks forward to continued joint endeavor to validate radiosurgery as a science and confirm the clinical usefulness of the CyberKnife System.
Erasmus MC installed its first CyberKnife Robotic Radiosurgery System in 2004, making it the fourth installation, in Europe, India, Mid East and Africa, during that period. Till date, Erasmus MC has provided therapy to over 1,000 patients with the CyberKnife System besides carrying out significant clinical research. It has also implemented innovative research techniques to study the performance of the CyberKnife System.
During the last quarter, Accuray revealed two more collaboration and research agreements with the University of Heidelberg and the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ), both in Heidelberg, Germany.
Accuray is a renowned radiation oncology company with a history of rapid innovation and cutting-edge technologies. CyberKnife and the TomoTherapy Systems comprise two of its flagship products. CyberKnife is a full body radiosurgery device used to treat cancerous tumors and TomoTherapy Systems are fully integrated and advanced radiation therapy systems for all types of cancer treatments.
The company installed 22 new CyberKnife and TomoTherapy systems during the most recent quarter, taking the aggregate global installed base to 635 units. The company added $64.2 million of new system orders in the quarter, leading to a total system backlog of $279.6 million.
However, Accuray remains susceptible to reimbursement uncertainties and faces stiff challenges from competitive product offerings of Varian Medical Systems ( VAR - Analyst Report ) . We currently have a Neutral recommendation on Accuray. The stock currently retains a short-term Zacks #3 Rank (Hold).
Read the full reports :
Analyst Report on VAR
Analyst Report on ARAY